|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-8-1
|
|
pubmed:abstractText |
In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE had limitations for assessing fracture risk. In a subset of 386 women, 7 years of raloxifene treatment significantly increased lumbar spine and femoral neck BMD compared from the baseline of MORE.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0884-0431
|
|
pubmed:author |
pubmed-author:Continuing Outcomes Relevant to Evista (CORE) Investigators,
pubmed-author:CummingsSteven RSR,
pubmed-author:Diez-PerezAdolfoA,
pubmed-author:EastellRichardR,
pubmed-author:GoemaereStefanS,
pubmed-author:HarrisSteven TST,
pubmed-author:KulkarniPandurang MPM,
pubmed-author:QuYongmingY,
pubmed-author:SiddhantiSuresh RSR,
pubmed-author:SirisEthel SES,
pubmed-author:SongJingliJ,
pubmed-author:StockJohn LJL,
pubmed-author:WongMaymeM,
pubmed-author:ZanchettaJose RJR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1514-24
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16059623-Aged,
pubmed-meshheading:16059623-Bone Density,
pubmed-meshheading:16059623-Bone Density Conservation Agents,
pubmed-meshheading:16059623-Bone Remodeling,
pubmed-meshheading:16059623-Bone and Bones,
pubmed-meshheading:16059623-Breast Neoplasms,
pubmed-meshheading:16059623-Double-Blind Method,
pubmed-meshheading:16059623-Female,
pubmed-meshheading:16059623-Femoral Neck Fractures,
pubmed-meshheading:16059623-Femur Neck,
pubmed-meshheading:16059623-Fracture Healing,
pubmed-meshheading:16059623-Fractures, Bone,
pubmed-meshheading:16059623-Humans,
pubmed-meshheading:16059623-Lumbar Vertebrae,
pubmed-meshheading:16059623-Middle Aged,
pubmed-meshheading:16059623-Osteoporosis,
pubmed-meshheading:16059623-Osteoporosis, Postmenopausal,
pubmed-meshheading:16059623-Placebos,
pubmed-meshheading:16059623-Poisson Distribution,
pubmed-meshheading:16059623-Postmenopause,
pubmed-meshheading:16059623-Proportional Hazards Models,
pubmed-meshheading:16059623-Raloxifene,
pubmed-meshheading:16059623-Risk,
pubmed-meshheading:16059623-Time Factors,
pubmed-meshheading:16059623-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
|
|
pubmed:affiliation |
Toni Stabile Osteoporosis Center, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. es27@columbia.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
